Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cNP5
- Development stage
- Preclinical
- Lead developer
- Neomatrix Therapeutics
- Administration
- Topical
01
Overview
cNP5 is a topical drug candidate under development by NeoMatrix Therapeutics. Its pre-Investigational New Drug (IND) work was supported by a grant from the USAMRDC. While the specific mechanism of action is not detailed in the provided context, it is being developed as a topical treatment, and its association with NeoMatrix Therapeutics' other drug candidate, NMT-cP12, suggests a potential indication for serious burn injuries.
Beyond the preview
Go deeper on cNP5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cNP5.